Effect of a combination of Nitazoxanide, Ribavirin and Ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19

https://doi.org/10.1002/jmv.26880

NCT04392427- This non-randomized controlled trial included 62 patients on triple combination treatment versus 51 age- and sex-matched patients on routine supportive treatment all of them confirmed case by positive RT-PCR of nasopharyngeal swab. Trial results showed that the clearance rates were 0% and 58.1% at 7th day and 13.7% and 73.1% at the 15th day in supportive treatment and combined antiviral groups, respectively. The cumulative clearance rates at 15th day are 13.7 and 88.7% in supportive treatment and combined antiviral groups, respectively. This trial concluded that combined use of Nitazoxanide, Ribavirin, and Ivermectin plus zinc supplement effectively clear the SARS-COV2 from nasopharynx in shorter time than the symptomatic therapy.

Tags: ,